Mitazalimab

Alligator Bioscience (STO:ATORX) Johan Giléus, currently CFO, has been appointed CEO effective 1 January 2027 Søren Bregenholt will remain CEO until 31 December 2026, ensuring a seamless transition Johan Giléus will combine the CEO and CFO roles, reflecting the refocusing of Alligator towards its financial interest in HLX22 LUND, SE / ACCESS Newswire / October 4, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a biotechnology company whose principal value driver is a financial interest in the HER2-targeting antibody programme HLX22, today announced that the Board of Directors has appointed Johan Giléus as Alligator's new Chief Executive Officer (CEO), effective 1 January 2027. The appointment follows Alligator's strategic refocusing towards its financial interest in HLX22, as announced on 23 July 2026. Johan Giléus succeeds Søren Bregenholt, who will remain CEO until 31 December 2026. Johan Giléus will continue in parallel as CFO. Following the transition, Alligator will operate with a minimal organisation, supported by the Board of Directors and external consultants. "On behalf of the Board of Directors, I would like to extend our deepest gratitude to Søren for his outstanding leadership and dedicated work over the last five years. Søren has led Alligator with great energy, integrity and commitment through a demanding period for the biotech sector, and he and his team have truly left no stone unturned. Even if the outcome with mitazalimab did not meet our expectations, Søren has steered Alligator through the strategic refocusing with professionalism and care, and we are very grateful for everything he has contributed," said Hans-Peter Ostler, Chairman of Alligator's Board of Directors. "We are pleased to secure a seamless transition with Johan, who knows Alligator and our financial interest in HLX22 in depth, and we are glad that Alligator will continue to benefit from Søren's experience during the transition." Johan Giléus has more than 30 years of experience from senior positions, of which the last nine years in the Swedish biotech industry. He joined Alligator as CFO in August 2024 and has since then formed the management team together with Søren Bregenholt. He joined Deloitte Sweden in 1991, where he worked primarily with M&A and financial reporting, and left the partnership in 2015. For further information, please contact: Hans-Peter Ostler, Chairman of the Board of Directors Investor Relations E-mail: ir@alligatorbioscience.com Phone: +46 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 3:45 p.m. CEST on 4 October 2026. About Alligator Bioscience Alligator is a biotechnology company that has historically focused on tumor-directed immuno-oncology. Following a strategic refocus, Alligator is prioritizing the value of its economic interest in HLX22, an anti-HER2 monoclonal antibody being developed by Shanghai Henlius Biotech Inc., from which Alligator is entitled to a share of revenues without incurring development costs. The Company has discontinued further internal development of mitazalimab and is seeking to out-license or divest the asset. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com . Attachments Alligator Bioscience appoints Johan Giléus as CEO - Søren Bregenholt to step down at year-end SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire

Sumeet Ambarkhane, M.D. Chief Medical Officer, Cytospire Dr Ambarkhane brings proven 20+ year track record advancing innovative cancer therapies through clinical development and regulatory approval Appointment strengthens Cytospire's executive leadership team as the Company prepares CYT X300 for first-in-human clinical studies LONDON, UK – 08 September 2026 – Cytospire Therapeutics Limited ("Cytospire"), a UK-based biotechnology company developing differentiated multispecific immune cell engager antibodies designed to enhance and direct the activity of the body's own immune system, today announces the appointment of Sumeet Ambarkhane, M.D., as Chief Medical Officer (CMO). Dr Ambarkhane is a physician-scientist and biotechnology executive with more than 20 years of experience in the US and Europe spanning clinical medicine, drug development, regulatory strategy and commercialisation. He joins Cytospire as the Company advances CYT X300, its lead pan-gamma delta T cell engager programme, towards clinical development as a potential treatment for EGFR-positive solid tumours, such as colorectal, head and neck and non-small cell lung cancers. Most recently, Dr Ambarkhane served as CMO of Pathios Therapeutics, where he led the clinical development strategy for the company's immuno-oncology pipeline, including early clinical development of its lead programme, PTT-4256. Prior to Pathios, he was CMO at Alligator Bioscience, where he played a key role in advancing the company's tumour-directed immuno-oncology portfolio and supporting the progression of mitazalimab towards Phase 3 development in pancreatic cancer. Earlier in his career, Dr Ambarkhane served as Senior Global Program Medical Director at MorphoSys, where he led clinical development activities for tafasitamab (Monjuvi®/Minjuvi®) from early through confirmatory development, regulatory approvals in major markets and the global development collaboration for various B-cell malignancies with Incyte Pharmaceuticals. He also held positions of increasing responsibility at UCB across immunology and neurology development programmes. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Dr Ambarkhane obtained his Bachelor of Medicine and Bachelor of Surgery degree and Medical Doctorate degrees in Medicine and Clinical Pharmacology from Seth G.S. Medical College and King Edward Memorial Hospital, University of Mumbai, India. "Sumeet brings deep immuno-oncology expertise and extensive experience advancing innovative therapies through clinical development and regulatory interactions. His track record of translating promising science into successful clinical programmes will be invaluable as we prepare to bring CYT X300 into the clinic and continue building Cytospire as a leading developer of next-generation immune cell engager therapies," said Natalie Mount, Chief Executive Officer of Cytospire . "Cytospire has developed a highly differentiated, tumour-targeted approach to engaging gamma delta T cells with the potential to address important limitations of existing immunotherapies," said Dr Sumeet Ambarkhane . "I am excited to join the Company at this important stage in its journey and look forward to working with the team to advance CYT X300 and the broader pipeline towards the clinic, with the goal of delivering meaningful new treatment options for patients with cancer." About Cytospire Therapeutics ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); Cytospire is developing an innovative portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells. Our core technology allows binding and activation of both tissue/tumour and blood resident gamma delta T cells. This opens a path to safer and more efficacious targeting of well-validated antigens that are intractable to CD3 T cell engagers due to toxicity. There are broad opportunities for Cytospire’s gamma delta T cell engagers in solid and haematological malignancies, as well as in autoimmune disease. Based in London, UK, Cytospire Therapeutics is backed by a strong syndicate of life science investors including Abingworth, 4BIO Capital, Servier Ventures, British Business Bank, Sound Bioventures, LifeArc Ventures and Criteria Bio Ventures. For more information, visit Contacts ezstandalone.cmd.push(function () { ezstandalone.showAds(133); }); Andrew Fadden, Chief Business Officer contact@cytospiretx.com Frazer Hall, Mark Swallow MEDiSTRAVA cytospire@medistrava.com Attachment Sumeet Ambarkhane, M.D.